Nexalin Technology Appoints New CEO, Directors, and Adjusts Compensation

Ticker: NXL · Form: 8-K · Filed: Jul 30, 2024 · CIK: 1527352

Sentiment: neutral

Topics: leadership-change, executive-compensation, board-of-directors

Related Tickers: NXL

TL;DR

Nexalin gets a new CEO (Jianjun Li) and two new directors, with updated exec pay.

AI Summary

Nexalin Technology, Inc. announced on July 29, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Jianhua Wang and Mr. Jianjun Li, and appointed Mr. Jianjun Li as Chief Executive Officer. The company also entered into new employment agreements with its Chief Executive Officer and Chief Financial Officer, with specific compensation details outlined in the filing.

Why It Matters

This filing indicates significant leadership changes and potential shifts in the company's strategic direction and financial planning under new executive leadership.

Risk Assessment

Risk Level: medium — Changes in leadership and executive compensation can signal strategic shifts or financial restructuring, introducing uncertainty.

Key Players & Entities

FAQ

Who were the newly elected directors of Nexalin Technology, Inc.?

Dr. Jianhua Wang and Mr. Jianjun Li were elected as new directors.

Who has been appointed as the new Chief Executive Officer?

Mr. Jianjun Li has been appointed as the new Chief Executive Officer.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is July 29, 2024.

What other officer positions were affected by the appointments?

The filing mentions new employment agreements for the Chief Executive Officer and Chief Financial Officer, implying changes or confirmations related to these roles.

What is the state of incorporation for Nexalin Technology, Inc.?

Nexalin Technology, Inc. is incorporated in Delaware.

Filing Stats: 462 words · 2 min read · ~2 pages · Grade level 11.8 · Accepted 2024-07-30 17:29:21

Key Financial Figures

Filing Documents

02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 29, 2024, Michael Nketiah submitted his resignation as the Senior Vice President of Clinical, Quality, & Regulatory Affairs of Nexalin Technology Inc. (the "Company"). Mr. Nketiah's resignation will be effective on August 16, 2024. He will continue to serve the Company as its Senior Vice President of Clinical, Quality, & Regulatory Affairs until such effective date. Mr. Nketiah advised that he is departing the Company to pursue another professional opportunity. Mr. Nketiah's resignation is not the result of any disagreement with the Company. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. NEXALIN TECHNOLOGY, INC. By: /s/ Mark White Mark White Chief Executive Officer Dated: July 30, 2024 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing